Navigation Links
MacroChem Announces Preferred Stock Conversions and $3.5 Million Private Placement
Date:10/10/2007

WELLESLEY HILLS, Mass., Oct. 10 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM) announced today that all the holders of its Series C Preferred Stock have converted their shares of preferred stock into 12,571,850 shares of common stock, and the warrants to purchase 8,648,102 shares of common stock previously issued with the Series C Preferred Stock have been reset to purchase 17,885,848 shares with an exercise price of $.60 per share pursuant to anti-dilution provisions in the warrants. In connection with the transaction, the Company closed a private placement of $3.5 million in gross proceeds, issuing 5,891,667 shares of common stock and five-year warrants to purchase 1,767,500 shares of common stock exercisable at $.60 per share. Griffin Securities, Inc. acted as placement agent in connection with the private placement.

"We're pleased with the support and confidence of our shareholders and new investors participating in this transaction," stated Robert J. DeLuccia, President and Chief Executive Officer of MacroChem. "We believe this transaction will simplify our capital structure by leaving only common stock, warrants and options outstanding, enable us to continue advancing EcoNail(R) through its Phase 2 clinical program and initiate development work on our newly acquired product, pexiganan, which has already completed two Phase 3 trials."

The securities offered and sold to the investors in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act") and were sold in reliance upon the exemption from securities registration afforded by Regulation D under the Securities Act. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such s
'/>"/>

SOURCE MacroChem Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)..., ANAHEIM, Calif., Dec. 4 Pamela ...hcare, was selected as a finalist for the "Chief I...scent,s business with the power of cloud computing...ir innovative usage of Salesforce CRM or the Force...uccess to their sales, marketing, partner, service...
(Date:12/4/2009)... with mice, scientists at Johns Hopkins publishing...hat a protein made by a gene called "Twist" may be...nguish stem cells that drive aggressive, metastati..., Building on recent work suggesting that it is a ...umors that drives breast cancer, scientists have s...
(Date:12/4/2009)...me whether procedure done immediately or 3 weeks l...althDay News) -- Timing of surgical repair or reco...not affect patient outcome, a new study has found....traumatic knee dislocations that can occur in high...mal time to perform surgery to repair these injuri...
(Date:12/4/2009)...d surveillance urged for at-risk patient groups ,...e childhood cancers, particularly Ewing sarcomas a...f late recurrence, U.S. researchers have found. ,...e-year survivors of the most common pediatric canc...ivor Study. , The researchers found that the ov...
(Date:12/4/2009)... found they spurred blood vessel growth after hear...ews) -- Adult stem cells appear to help repair hea...e 1 study of 53 patients found that stem cells fro...od vessels in heart tissue damaged by heart attack...ons within 10 days of having a heart attack. Durin...
Breaking Medicine News(10 mins):Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2
...End the Tobacco Settlement Spending Spree and Dire...TON, Nov. 19 This Sunday, November 23, 2008, will...he largest civil settlement in United States histo...for smoking-caused health care costs and imposed m...
...endations for System in Critical Need of Reform , ...ety policy, organization and communications were a...onella Saintpaul, according to a report released t...ssons to Be Learned from the 2008 Salmonella Saint...
...weight-loss surgery, known as bariatric surgery, a...e at lower risk for pregnancy-related diabetes and...iously affect the mother or her baby -- than pregn... JAMA. , , The findings are part of an evide...
...airman, Tony Strange Appointed to CEO position and..., MELVILLE, N.Y., Nov. 18 /PRNewswire-FirstCall/...V ), a leading provider of comprehensive home heal...ome the Company,s Chief Executive Officer in addit...
...ntract , , BUFFALO, N.Y., Nov. 18 Representa...ations joined Teamsters Local 375 today to show su... paramedics employed by Rural/Metro. , , The ...ear-round. The company and the Teamsters are retur...
...t reverse, prevent autoimmune disease , , ...nder drug that effectively treats leukemia and oth...ersity of California San Francisco, researchers r...tes is usually diagnosed in children and young adu...
Other Medicine News:Health News:November 23 Marks Tenth Anniversary of the Largest Civil Settlement in U.S. History 2Health News:November 23 Marks Tenth Anniversary of the Largest Civil Settlement in U.S. History 3Health News:Salmonella Saintpaul Outbreak Exposes Food Safety Weaknesses 2Health News:Salmonella Saintpaul Outbreak Exposes Food Safety Weaknesses 3Health News:Some Pregnancy-Related Complications Minimized for Women Who Have Had Weight-Loss Surgery 2Health News:Some Pregnancy-Related Complications Minimized for Women Who Have Had Weight-Loss Surgery 3Health News:Gentiva Health Services Confirms Management Succession 2Health News:Gentiva Health Services Confirms Management Succession 3Health News:Gentiva Health Services Confirms Management Succession 4Health News:Community, Labor Organizations Rally for Buffalo EMTs, Paramedics 2Health News:Cancer Drugs May Treat Type 1 Diabetes 2
(Date:12/4/2009)...c. 4 Suneva Medical, a privately-h...ced the appointment of Philip Ranker as Vice Presi...r. Ranker will lead all Suneva Medical,s general a...ounting, IT, IR, administration and human resource...agement team. ,, "One of my key objectives as ...
(Date:12/4/2009)... Drs. Neal Shore and E. David Crawf...n (PSA) recurrence from the additional analysis of...te in a Phase III pivotal study of FIRMAGON® ...olide in prostate cancer patients during the first...received FIRMAGON 240/80 mg/month had a recurrence...
(Date:12/3/2009)... Allen Medical Systems, ...RC ), today announced the launch of its new Allen ...business website www.AllenAmatech.com . ,, ... identity and includes an online version of the ne...design specifications for the products. "We hope t...
Breaking Medicine Technology:Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2Accelerated Development of New Treatment for Multi Drug Resistant Tuberculosis 3A TB Alliance and Tibotec Announce Unique Partnership to Develop TMC20 49213 1Accelerated Development of New Treatment for Multi Drug Resistant Tuberculosis 3A TB Alliance and Tibotec Announce Unique Partnership to Develop TMC20 49213 2Accelerated Development of New Treatment for Multi Drug Resistant Tuberculosis 3A TB Alliance and Tibotec Announce Unique Partnership to Develop TMC20 49213 3AMDL CEO Featured in CEOCFO Magazine 3B Details Progress on DR 70 International Commercialization Strategy 26 Confidence in FY2009 Financial Forecast 49211 1AMDL CEO Featured in CEOCFO Magazine 3B Details Progress on DR 70 International Commercialization Strategy 26 Confidence in FY2009 Financial Forecast 49211 2AMDL CEO Featured in CEOCFO Magazine 3B Details Progress on DR 70 International Commercialization Strategy 26 Confidence in FY2009 Financial Forecast 49211 3Hartford grants increase support for geriatric social work training 49209 1Hartford grants increase support for geriatric social work training 49209 2Hartford grants increase support for geriatric social work training 49209 3
...ne in the Treatment of Patients with Relapsed/Ref...ented Tomorrow, Tuesday, June 3rd at 12:0...rmaceuticals,Inc. (Nasdaq: KERX ) today announced...ave been selected for both poster presentation and...al Oncology Meeting,currently taking place in Chic...
...erican Society of Clinical Oncology (ASCO),annual ...vival vs. external c...c.,(Nasdaq: IDMI ) today announced follow-up resu...t the product candidate was well tolerated, induce...sponses, and showed a,positive survival trend in H...
Other Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois 2Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois 3Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois 4Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois 5IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients 2IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients 3IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients 4
Disposable Lacrimal Dilators
Reusable Double Dilators
Skin Tone External Eyelid Weights
Contour Design Eyelid Implants (Gold)
Medicine Products: